Q2 EPS Estimates for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Zacks Research boosted their Q2 2026 earnings estimates for shares of Gilead Sciences in a research report issued on Friday, April 4th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings per share of $1.84 for the quarter, up from their previous forecast of $1.83. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2026 earnings at $2.29 EPS, FY2026 earnings at $8.02 EPS, Q1 2027 earnings at $1.88 EPS and FY2027 earnings at $8.62 EPS.

Several other brokerages also recently weighed in on GILD. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Bank of America upped their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Morgan Stanley raised their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Stock Down 4.6 %

GILD stock opened at $107.25 on Monday. The business has a 50 day moving average of $107.30 and a 200 day moving average of $95.98. The firm has a market cap of $133.54 billion, a PE ratio of 289.86, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date was Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently bought and sold shares of the business. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership purchased a new position in Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC grew its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.